| Literature DB >> 26992095 |
Manyoel Lim1, Meyke Roosink1,2, June Sic Kim3, Hye Won Kim4,5, Eun Bong Lee4, Kyeong Min Son6, Hyun Ah Kim6,7, Chun Kee Chung1,3,8.
Abstract
The aim of this study was to investigate augmented pain processing in the cortical somatosensory system in patients with fibromyalgia (FM). Cortical evoked responses were recorded in FM (n = 19) and healthy subjects (n = 21) using magnetoencephalography after noxious intra-epidermal electrical stimulation (IES) of the hand dorsum (pain rating 6 on a numeric rating scale, perceptually-equivalent). In addition, healthy subjects were stimulated using the amplitude corresponding to the average stimulus intensity rated 6 in patients with FM (intensity-equivalent). Quantitative sensory testing was performed on the hand dorsum or thenar muscle (neutral site) and over the trapezius muscle (tender point), using IES (thresholds, ratings, temporal summation of pain, stimulus-response curve) and mechanical stimuli (threshold, ratings). Increased amplitude of cortical responses was found in patients with FM as compared to healthy subjects. These included the contralateral primary (S1) and bilateral secondary somatosensory cortices (S2) in response to intensity-equivalent stimuli and the contralateral S1 and S2 in response to perceptually-equivalent stimuli. The amplitude of the contralateral S2 response in patients with FM was positively correlated with average pain intensity over the last week. Quantitative sensory testing results showed that patients with FM were more sensitive to painful IES as well as to mechanical stimulation, regardless of whether the stimulation site was the hand or the trapezius muscle. Interestingly, the slope of the stimulus-response relationship as well as temporal summation of pain in response to IES was not different between groups. Together, these results suggest that the observed pain augmentation in response to IES in patients with FM could be due to sensitization or disinhibition of the cortical somatosensory system. Since the S2 has been shown to play a role in higher-order functions, further studies are needed to clarify the role of augmented S2 response in clinical characteristics of FM.Entities:
Mesh:
Year: 2016 PMID: 26992095 PMCID: PMC4798786 DOI: 10.1371/journal.pone.0151776
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Demographics and clinical characteristics of the participants.
| FM (n = 19) | HC (n = 21) | p [Group] | |
|---|---|---|---|
| Age (years) | 44.9 ± 8.3 | 44.8 ± 8.2 | 0.958 |
| Education (years) | 13.1 ± 2.2 | 12.9 ± 2.7 | 0.853 |
| Occupation (working), n (%) | 10 (53%) | 13 (62%) | 0.554 |
| Marital status (married), n (%) | 16 (84%) | 17 (81%) | 0.787 |
| Medication, n (%) | |||
| Analgesics/muscle relaxants/NSAIDs | 14 (74%) | − | − |
| Antidepressants | 14 (74%) | − | − |
| Anticonvulsants | 7 (37%) | − | − |
| BAI (0–63) | 23.3 ± 10.8 | 1.8 ± 2.0 | |
| BDI (0–63) | 19.0 ± 6.8 | 2.8 ± 3.9 | |
| PSQI (0–21) | 13.0 ± 3.4 | 3.1 ± 1.2 | |
| TP manual (0–18) | 15.7 ± 1.8 | 1.7 ± 2.3 | |
| TP algometer (0–18) | 14.2 ± 3.8 | 1.9 ± 1.7 | |
| FIQ (0–100) | 62.5 ± 13.2 | − | − |
| Pain duration (months) | 35.6 ± 31.1 | − | − |
| Pain intensity—last week (mm) | 57.2 ± 20.1 | − | − |
| SF-MPQ sensory (0–33) | 14.7 ± 6.8 | − | − |
| SF-MPQ affective (0–12) | 5.8 ± 2.6 | − | − |
| SF-MPQ total (0–45) | 20.5 ± 8.8 | − | − |
Data are presented as mean ± SD or number of subjects (%). Pain intensity (visual analog scale) was determined before QST and MEG assessments. FM: fibromyalgia, HC: healthy controls, NSAIDs: nonsteroidal anti-inflammatory drugs, BAI: Beck’s anxiety inventory, BDI: Beck’s depression inventory, PSQI: Pittsburgh sleep quality index, TP: tender points, FIQ: fibromyalgia impact questionnaire, SF-MPQ: short-form McGill pain questionnaire. p-values are based on independent t-tests (continuous variables) and X2-tests (categorical variables) with factor [Group]. Significant p-values (p < 0.05) are depicted in bold type.
Quantitative sensory testing.
| Test | Site | Outcome | FM (n = 19) | HC (n = 21) | p [Group] | p [Site] |
|---|---|---|---|---|---|---|
| TDT | H | Rating (0–10) | 0 [0–0] | 0 [0–0] | 0.134 | 0.134 |
| T | Rating (0–10) | 0 [0–1] | 0 [0–0] | |||
| PIN | H | Rating (0–10) | 2 [0–5] | 0 [0–3] | ||
| T | Rating (0–10) | 3 [0–7] | 0 [0–3] | |||
| PPT | H | Threshold (kPa) | 2.83 [1.53–4.73] | 3.77 [2.70–4.50] | ||
| Rating (0–10) | 3 [1–6] | 2 [1–4] | 0.427 | |||
| T | Threshold (kPa) | 2.10 [1.43–5.75] | 3.17 [2.20–4.67] | |||
| Rating (0–10) | 3 [1–7] | 2 [0–4] | ||||
| EST | H | Threshold (mA) | 0.15 [0.10–0.27] | 0.15 [0.10–0.28] | 0.856 | 0.388 |
| Rating (0–10) | 0 [0–3] | 0 [0–0] | 0.131 | |||
| T | Threshold (mA) | 0.15 [0.05–0.48] | 0.15 [0.10–0.45] | |||
| Rating (0–10) | 0 [0–1] | 0 [0–0] | ||||
| EPT | H | Threshold (mA) | 1.00 [0.60–1.80] | 1.30 [0.80–3.90] | 0.097 | |
| Rating (0–10) | 3 [1–5] | 2 [1–4] | 0.797 | |||
| T | Threshold (mA) | 1.10 [0.60–2.80] | 1.20 [0.80–3.50] | |||
| Rating (0–10) | 3 [1–4] | 1 [1–3] | ||||
| EPTT | H | Threshold (mA) | 2.83 [1.83–6.00] | 5.33 [2.50–8.50] | 0.986 | |
| Rating (0–10) | 6 [4–8] | 4 [2–7] | 0.320 | |||
| T | Threshold (mA) | 2.50 [1.50–7.07] | 5.08 [2.33–12.50] | |||
| Rating (0–10) | 6 [3–8] | 5 [3–7] |
Data are presented as median [min—max]. FM: fibromyalgia, HC: healthy controls, TDT: tactile detection threshold, PIN: pinprick stimulation, PPT: pressure pain threshold, EST: electrical sensation threshold, EPT: electrical pain threshold, EPTT: electrical pain tolerance threshold, H: hand (dorsum or thenar muscle), T: trapezius muscle.
*Some subjects did not report tolerance at the highest stimulation level. Since this occurred in both patients and controls alike, and since we did not set a cut-off threshold (mA) for the forehand, it was decided to exclude these subjects from the EPTT analyses. As such, the final number of subjects for the EPTT analyses were: for the hand FM (n = 18), and for the trapezius muscle FM (n = 16) and HC (n = 16), and repeated measures ANOVA for the EPTT was based on FM (n = 16) and HC (n = 16). For QST thresholds and ratings, p-values were based on univariate results of repeated measures ANOVA using log-normalized data with factors [Group] and [Site]. Significant p-values (p < 0.05) are depicted in bold type. No significant interaction effects were found.
Fig 1Stimulus-response curve (A) and temporal summation of pain (B) in response to standardized intra-epidermal electrical stimulation. Grey squares/bars represent patients with FM (A: n = 19, B: n = 18), white squares/bars represent HC subjects (n = 21). The levels of stimulation (x-axis) were based on individual pain thresholds. PT_25%, PT_100%, PT_175% and PT_250% correspond to 25%, 100%, 175% and 250% of the pain threshold intensity (mA), respectively. Data are expressed as the mean ± SEM.
Fig 2Spatial distribution of the MEG responses in a representative FM (A) and HC subjects (B). The head is viewed from the top. The trace of each gradiometer response pair represents the magnetic field derivation along the latitude (upper) and longitude (lower). The inserts on the right indicate the enlarged responses recorded from the contralateral S1 (a), contralateral S2 (b) and ipsilateral S2 (c) regions. The black lines represent the cortical response to the NRS 6 (FM) and perceptually-equivalent (HC) conditions. The grey line represents the cortical response to the intensity-equivalent condition (HC only). The vertical dotted lines indicate the stimulus onset.
Fig 3Group mean source locations (A) and source waveforms (B). (A) The group mean source locations for the NRS6 condition (FM) in blue and for the perceptually-equivalent condition (HC-PE) in cyan superimposed on a standard brain. (B) The group mean source waveform as a function of time. The NRS6 condition (FM) in blue, HC-PE in cyan and the intensity-equivalent condition (HC-IE) in gray. The vertical line indicates the stimulus onset.
Mean source locations for the NRS6 (FM) and perceptually-equivalent (HC-PE) conditions.
| FM | HC-PE | |||||
|---|---|---|---|---|---|---|
| cS1 (n = 14) | cS2 (n = 18) | iS2 (n = 18) | cS1 (n = 15) | cS2 (n = 21) | iS2 (n = 21) | |
| | -32.0 ± 8.3 | -42.5 ± 7.8 | 41.9 ± 6.2 | -31.3 ± 8.6 | -47.7 ± 7.8 | 47.5 ± 5.9 |
| | 1.7 ± 8.0 | 14.4 ± 8.4 | 15.8 ± 8.2 | -1.6 ± 7.1 | 12.9 ± 6.4 | 12.9 ± 6.8 |
| | 85.1 ± 8.4 | 58.9 ± 6.8 | 60.2 ± 8.4 | 91.6 ± 7.3 | 59.5 ± 8.7 | 61.1 ± 6.7 |
| | -34.4 ± 6.7 | -46.8 ± 7.1 | 43.9 ± 7.0 | -35.0 ± 8.7 | -50.4 ± 7.2 | 50.2 ± 7.8 |
| | -29.5 ± 9.5 | -9.7 ± 6.4 | -9.7 ± 8.0 | -32.6 ± 10.6 | -11.5 ± 8.2 | -11.8 ± 6.2 |
| | 45.5 ± 9.6 | 18.4 ± 7.1 | 21.0 ± 9.7 | 53.4 ± 6.0 | 20.6 ± 9.2 | 22.6 ± 8.0 |
| GOF (%) | 92.7 ± 5.8 | 92.4 ± 4.5 | 91.6 ± 5.6 | 90.4 ± 6.3 | 90.1 ± 5.7 | 91.3 ± 7.6 |
Data are expressed as the mean ± SD. Twenty HC subjects whose MRI data were available were included in deriving the source location in the Talairach coordinates. FM: fibromyalgia, HC: healthy controls, cS1: contralateral primary somatosensory cortex; cS2: contralateral secondary somatosensory cortex; iS2: ipsilateral secondary somatosensory cortex; GOF: Goodness-of-fit; n: number of subjects included in the analysis.
Fig 4The amplitudes of the cS1, cS2 and iS2 in patients with FM and HC subjects.
Repeated measures ANOVAs and independent t-tests showed that cortical responses in response to intra-epidermal electrical stimulation of the hand were higher in patients with FM as compared to both perceptually-equivalent (HC-PE) and intensity-equivalent (HC-IE) conditions in HC subjects. Data are expressed as the mean ± SEM. *p < 0.05, **p < 0.01.
Peak latencies and peak amplitudes of the S1 and S2 sources.
| Latency (ms) | Amplitude (nAm) | |||||
|---|---|---|---|---|---|---|
| cS1 | cS2 | iS2 | cS1 | cS2 | iS2 | |
| FM | 137.7 ± 28.7 | 129.5 ± 27.5 | 148.1 ± 28.5 | 20.4 ± 7.0 | 42.4 ± 21.3 | 36.1 ± 20.9 |
| HC-PE | 132.8 ± 26.5 | 120.8 ± 13.6 | 137.5 ± 23.4 | 15.1 ± 4.1 | 30.0 ± 13.1 | 26.4 ± 14.6 |
| HC-IE | 135.6 ± 29.2 | 125.0 ± 17.1 | 146.0 ± 22.1 | 12.6 ± 4.5 | 24.2 ± 12.2 | 20.2 ± 10.6 |
Data are expressed as mean ± SD. FM: fibromyalgia; HC-PE: perceptually-equivalent condition in healthy controls; HC-IE: intensity-equivalent condition in healthy controls; cS1: contralateral primary somatosensory cortex; cS2: contralateral secondary somatosensory cortex; iS2: ipsilateral secondary somatosensory cortex.
Fig 5Relationship between the dipole amplitude in the cS2 and clinical pain intensity (VAS, mm).